Company: SMNR
Filing Date: 2025-03-25
Form Type: PRER14A
Source: 0001013762-25-002297
Chunk: 20

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-03-25
Form: PRER14A
Chunk 20
---
                                                                                                                                                                                                                                                                                                                                                                    
 Telephone No.: (646) 978-5180                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                                            |     | You may also obtain additional information about the Company from documents filed with the SEC by following the instructions in the section entitled “Where You Can Find More Information.”                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

12 FORWARD-LOOKING STATEMENTS Some of the statements contained in this proxy statement constitute forward -lookingstatements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward -lookingstatements include, but are not limited to, our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including with our respect to our recently announced proposed business combination with Semnur. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward -lookingstatements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward -lookingstatements, but the absence of these words does not mean that a statement is not forward -looking. Forward -lookingstatements in this proxy statement may include, for example, statements about: •Our ability to effect the extension; •our ability to select an appropriate target business or businesses; •our ability to complete our initial business combination, including our recently announced proposed business combination with Semnur; •our expectations around the performance of the prospective target business or businesses; •our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination; •our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial business combination; •our potential ability to obtain additional financing to complete our initial business combination; •our pool of prospective target businesses; •our ability to consummate an initial business combination due to the uncertainty resulting from the ongoing military action with the country of Ukraine commenced by the Russian Federation and Belarus in February 2022, adverse changes in general economic industry and competitive conditions, or adverse changes in government regulation or prevailing market interest rates; •the ability of our officers and directors to generate a number of potential business combination opportunities; •our public securities’ potential